Australia's most trusted
source of pharma news
Posted 11 November 2024 PM
ASX-listed Mayne Pharma is remaining tight-lipped about media reports the company is being marketed to potential buyers in the hope of securing a lucrative exit for its shareholders who have seen their investment plumet in recent years.
The Australian Financial Review's Street Talk column, reported that investment bank Jeffries Australia is quietly shopping the pharma around with sources also noting that the company had been actively presenting at global healthcare conferences, including events hosted by Jefferies, JPMorgan, and HC Wainwright, suggesting that Mayne is keen to attract potential investors.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.